Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression.
Aleksandr M ReznikTimur S SyunyakovInessa AkhmerovaDaniil ButylinAnastasia VasilenkoAnton N GvozdeckiiTagir GizatullinGalina GilmanshinaEgor GolosovSergey KolchevLidiya LinovaDaniil MironAleksandr V MudrakIgor OleichikStepan SizovElena TarakanovaOlga ChesnokovaPublished in: Consortium psychiatricum (2022)
A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.